Open Payments

Osf Heart Of Mary Medical Center

Type
Teaching hospital
Where
Urbana, IL
Medicare CCN
140113
Received
$484,699 in 88 records, 2021 ($38,543 general, $446,155 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment12$38,543
2021Research payment76$446,155

By company

CompanyRecordsAmountYears
Janssen Research & Development, LLC16$254,7212021
Davol Inc.1$60,4862021
ENDOTRONIX, INC.1$52,8082021
Vifor (International) Ltd.39$26,5732021
Ethicon Inc.11$23,0222021
Medical Device Business Services, Inc.5$20,7952021
Chiesi USA, Inc.1$9,5002021
Ethicon US, LLC1$9,1252021
GE HEALTHCARE2$8,9302021
Roche Products Limited3$8,1292021
Biogen, Inc.3$4,4352021
KLS-Martin L.P.1$4,3132021
Abbott Laboratories3$1,6102021
Insulet Corporation1$2502021

By nature of payment

NatureRecordsAmount
Research payment76$446,155
Space rental or facility fees (teaching hospital only)6$25,108
Education1$9,125
Debt forgiveness4$4,060
Compensation for services other than consulting, including serving as faculty or as a speaker at a v1$250

Records

DateCompanyAmountNatureFormProductStudyYear
2021-12-31Ethicon US, LLC$9,125EducationIn-kind items and servicesSmartAblateTM System RF Generator Device, Generators2021
2021-12-27Ethicon Inc.$26Research paymentCash or cash equivalentResearch to further inform thinking about the role of LINX for Reflux Disease2021
2021-12-15Vifor (International) Ltd.$1,000Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-12-15Vifor (International) Ltd.$500Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-12-15Vifor (International) Ltd.$400Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-12-14Biogen, Inc.$1,400Research paymentCash or cash equivalentTECFIDERA Drug, NEUROLOGYDimethyl Fumarate (DMF) Observational Study2021
2021-11-29Ethicon Inc.$2,419Research paymentCash or cash equivalentResearch to further inform thinking about the role of LINX for Reflux Disease2021
2021-11-22Ethicon Inc.$26Research paymentCash or cash equivalentResearch to further inform thinking about the role of LINX for Reflux Disease2021
2021-11-19Ethicon Inc.$800Research paymentCash or cash equivalentResearch to further inform thinking about the role of LINX for Reflux Disease2021
2021-11-02Biogen, Inc.$1,500Research paymentCash or cash equivalentTECFIDERA Drug, NEUROLOGYDimethyl Fumarate (DMF) Observational Study2021
2021-11-02Abbott Laboratories$1,310Debt forgivenessCash or cash equivalent2021
2021-10-27Vifor (International) Ltd.$750Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-10-27Abbott Laboratories$100Debt forgivenessCash or cash equivalent2021
2021-10-27Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-10-25Chiesi USA, Inc.$9,500Research paymentCash or cash equivalentCUROSURF Drug, NEONATOLOGY2021
2021-10-19Abbott Laboratories$200Debt forgivenessCash or cash equivalent2021
2021-10-19Ethicon Inc.$166Research paymentCash or cash equivalentResearch to further inform thinking about the role of LINX for Reflux Disease2021
2021-10-12Roche Products Limited$250Research paymentCash or cash equivalentOCREVUS Biological, ImmunologyOBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT2021
2021-10-05Roche Products Limited$5,476Research paymentCash or cash equivalentOCREVUS Biological, ImmunologyOBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT2021
2021-09-15Vifor (International) Ltd.$1,577Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-09-15Vifor (International) Ltd.$1,027Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-09-13Janssen Research & Development, LLC$6,436Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-09-09GE HEALTHCARE$6,480Research paymentIn-kind items and servicesGE Ultrasound System Performance Evaluation R3 OSF Saint Francis Medical Center2021
2021-09-08Vifor (International) Ltd.$750Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-09-08Vifor (International) Ltd.$750Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-09-08Vifor (International) Ltd.$500Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-09-08Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-08-13Ethicon Inc.$1,538Research paymentCash or cash equivalentResearch to further inform thinking about the role of LINX for Reflux Disease2021
2021-08-11KLS-Martin L.P.$4,313Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-08-09Ethicon Inc.$951Research paymentCash or cash equivalentResearch to further inform thinking about the role of LINX for Reflux Disease2021
2021-07-29Janssen Research & Development, LLC$670Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-07-19Ethicon Inc.$2,948Research paymentCash or cash equivalentResearch to further inform thinking about the role of LINX for Reflux Disease2021
2021-07-12Ethicon Inc.$11,200Research paymentCash or cash equivalentResearch to further inform thinking about the role of LINX for Reflux Disease2021
2021-06-28Janssen Research & Development, LLC$7,380Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-06-28Insulet Corporation$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2021
2021-06-25Janssen Research & Development, LLC$29,379Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-06-25Janssen Research & Development, LLC$6,042Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-06-25Janssen Research & Development, LLC$1,585Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-06-25Janssen Research & Development, LLC$670Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-06-21Janssen Research & Development, LLC$10,947Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-06-21Ethicon Inc.$529Research paymentCash or cash equivalentResearch to further inform thinking about the role of LINX for Reflux Disease2021
2021-06-07Janssen Research & Development, LLC$335Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-05-24Ethicon Inc.$2,419Research paymentCash or cash equivalentResearch to further inform thinking about the role of LINX for Reflux Disease2021
2021-05-12Vifor (International) Ltd.$784Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-05-12Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-05-12Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-05-03Medical Device Business Services, Inc.$5,795Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-04-21Vifor (International) Ltd.$749Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-04-19Janssen Research & Development, LLC$38,528Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-04-15Roche Products Limited$2,403Research paymentCash or cash equivalentOCREVUS Biological, ImmunologyOBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT2021
2021-04-08Medical Device Business Services, Inc.$3,320Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-04-07Vifor (International) Ltd.$1,000Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-04-07Vifor (International) Ltd.$784Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-04-07Vifor (International) Ltd.$500Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-04-07Vifor (International) Ltd.$273Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-04-07Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-04-07Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-04-07Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-04-07Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-04-07Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-04-01ENDOTRONIX, INC.$52,808Research paymentCash or cash equivalentCORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILUREPROACTIVE-HF2021
2021-04-01Biogen, Inc.$1,535Research paymentCash or cash equivalentPLEGRIDY Biological, NEUROLOGYPlegridy Observational Program2021
2021-03-24Vifor (International) Ltd.$1,004Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-03-24Vifor (International) Ltd.$1,004Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-03-24Vifor (International) Ltd.$878Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-03-18Janssen Research & Development, LLC$2,010Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-03-18Janssen Research & Development, LLC$176Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-03-03Vifor (International) Ltd.$1,466Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-03-03Vifor (International) Ltd.$1,466Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-03-03Vifor (International) Ltd.$750Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-03-03Vifor (International) Ltd.$500Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-03-03Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-03-03Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-03-03Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-03-03Vifor (International) Ltd.$35Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-03-01Janssen Research & Development, LLC$39,955Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-02-24Vifor (International) Ltd.$3,564Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-02-24Vifor (International) Ltd.$1,378Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-02-24Vifor (International) Ltd.$1,378Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-02-24Vifor (International) Ltd.$1,378Research paymentCash or cash equivalentVeltassa Drug, Potassium BinderPAT-CR-3022021
2021-02-15Janssen Research & Development, LLC$44,942Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-02-15Janssen Research & Development, LLC$43,804Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-02-15Janssen Research & Development, LLC$21,861Research paymentCash or cash equivalentPhase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C2021
2021-02-15Medical Device Business Services, Inc.$2,195Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-02-03GE HEALTHCARE$2,450Debt forgivenessCash or cash equivalent2021
2021-01-28Medical Device Business Services, Inc.$4,840Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-01-19Medical Device Business Services, Inc.$4,645Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-01-04Davol Inc.$60,486Research paymentCash or cash equivalentDVL-HE-0182021

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Champaign CountyUrbana city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Urbana, IL, county Champaign County, IL, state Illinois; placed by its city name.

MeasurePlace (city or town)
Urbana, IL
County
Champaign County, IL
State
Illinois
Population B0100339,341208,74112,694,798
Population, 2020 census P138,336205,86512,812,508
Median age B0100226.130.739.0
Under 18 B0100113.2%19.1%21.8%
65 and over B0100111.5%13.9%17.0%
Households B1100116,85685,4725,036,449
Foreign born B0500221.2%14.2%14.7%
Median household income B19013$45,346$63,683$83,390
Median family income B19113$86,209$100,396$106,018
Per capita income B19301$32,592$38,439$46,406
Poverty rate B1700128.0%19.1%11.8%
Unemployment rate B230254.7%4.3%5.8%
Civilian labor force B2302520,316104,8766,652,134
Mean commute (minutes) B0801314.216.927.8
Bachelor's degree or higher B1500356.7%46.2%37.8%
Housing units B2500119,22895,1155,457,452
Owner-occupied B2500337.3%54.0%67.1%
Renters B2500362.7%46.0%32.9%
Median home value B25077$184,900$211,500$263,300
Median gross rent B25064$972$1,051$1,274
White, not Hispanic B0300252.9%62.4%58.1%
Black B0300218.7%13.4%13.3%
Hispanic or Latino B0300210.1%8.3%18.8%
Asian B0300214.2%11.4%5.9%
American Indian and Alaska Native B030020.0%0.1%0.1%

Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); Unemployment rate: 5.7% in Sep 2016 to 4.6% in Sep 2026; low 3.6%, high 18.3% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Urbana, IL.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.